<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536961</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-136</org_study_id>
    <nct_id>NCT04536961</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth&#xD;
      as various solid tablet prototypes, by healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Actual">December 25, 2020</completion_date>
  <primary_completion_date type="Actual">December 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986165</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986165</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to t (AUC (0-t)) of BMS-986165</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Part A, B, C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nonserious Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 60 days (for Parts A &amp; C), approximately 69 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 83 days (for Parts A &amp; C), approximately 92 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
    <description>The QT interval is the time from the start of the Q wave to the end of the T wave.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to approximately 53 days (for Parts A &amp; C), approximately 62 days (for Part B)</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Reference Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Prototype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Reference Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Prototype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Treatment 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Treatment- BMS-986165-01</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A: Reference Treatment</arm_group_label>
    <arm_group_label>Part C Reference Treatment</arm_group_label>
    <other_name>Deucravacitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prototype BMS-986165</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A Prototype</arm_group_label>
    <arm_group_label>Part B: Treatment 1</arm_group_label>
    <arm_group_label>Part B: Treatment 2</arm_group_label>
    <arm_group_label>Part B: Treatment 3</arm_group_label>
    <arm_group_label>Part B: Treatment 4</arm_group_label>
    <arm_group_label>Part B: Treatment 5</arm_group_label>
    <arm_group_label>Part C: Prototype</arm_group_label>
    <other_name>Deucravacitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part B: Treatment 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alcohol</intervention_name>
    <description>Specified quantity on specified days</description>
    <arm_group_label>Part B: Treatment 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  No clinically significant deviation from normal in medical history, physical&#xD;
             examination, electrocardiograms (ECGs), and clinical laboratory determinations.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and total body weight ≥50 kg&#xD;
             (110 lb). BMI = weight (kg)/(height [m])2 at screening.&#xD;
&#xD;
          -  Willing and able to consume 4 units of alcohol (Part B only)&#xD;
&#xD;
          -  A negative polymerase chain reaction (PCR) test for coronavirus disease 2019&#xD;
             (COVID-19) at screening and admission&#xD;
&#xD;
          -  Males and females must agree to follow specific methods of contraception, if&#xD;
             applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (within 3 months or 90 days of study drug administration) clinically&#xD;
             significant gastrointestinal disease that, in the opinion of the investigator or&#xD;
             medical monitor, could impact upon the absorption of study drug&#xD;
&#xD;
          -  Any medical condition that presents a potential risk to the participant and/or may&#xD;
             compromise the objectives of the study, including a history of or active liver&#xD;
             disease.&#xD;
&#xD;
          -  Clinically significant history or presence of acute or chronic bacterial, fungal, or&#xD;
             viral infection (eg, pneumonia, septicemia) within the 3 months or 90 days prior to&#xD;
             screening.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences Miami</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

